Glaxosmithkline Plc (GSK) 46.57 $GSK
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.42% Loss
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.57 (-0.67)
GlaxoSmithKline Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.57 (-0.67)
Moll Law Group Considering First Nationwide Class Action Suit Against Maker Of Anti-Nausea Drug Zofran
PR Newswire - Wed Apr 22, 11:15AM CDT
A Chicago law firm said today it is considering filing the first nationwide class action suit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.57 (-0.67)
GlaxoSmithKline (GSK) Roof Leaking Today
at The Street - Wed Apr 22, 9:21AM CDT
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
GSK: 46.57 (-0.67)
Rising Rates? Don't Hold Your Breath
Yieldpig - at Seeking Alpha - Wed Apr 22, 4:32AM CDT
HTGC: 14.00 (+0.18), MAT: 28.36 (+1.14), GSK: 46.57 (-0.67)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.44 (+0.18), GSK: 46.57 (-0.67), CELGZ: 2.87 (+0.04)
Summons Executed in Zofran Lawsuit Alleging Birth Defects
PRWeb - Wed Apr 22, 2:07AM CDT
Attorneys for Zofran lawsuits report progress on one of the first Zofran lawsuits that has been filed nationwide, which they now have pending in U.S. District Court in Northern Alabama.* According to these Zofran lawyers, a summons order has been acknowledged by the defendant, GlaxoSmithKline.
GSK: 46.57 (-0.67)
Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:50PM CDT
Switzerland-based Novartis AG (NVS), one of the leading players in the health care solutions, will be reporting its first-quarter 2015 results on Apr 23, 2015.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
ChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors
GlobeNewswire - Mon Apr 20, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that Jeff Baxter has joined the Company's Board of Directors as an Independent Director.
IMDZ: 26.66 (+0.22), VBIV: 2.65 (+0.01), GSK: 46.57 (-0.67)
The Weekender
Aviate - at Seeking Alpha - Sun Apr 19, 4:54AM CDT
But it is April Investors were scratching their heads trying to find reasons to justify this week's fall in markets: a potential Grexit, rising peripheral spreads, a slowing rate of incline in bank-lending to corporates (BLS), higher...
TI: 11.62 (-0.04), ALU: 4.12 (+0.09), GSK: 46.57 (-0.67), UL: 44.49 (-0.49), DEO: 112.35 (+0.02), NOK: 8.00 (+0.16), SPY: 210.63 (+1.03), NVO: 56.37 (-0.17), QQQ: 108.65 (+0.59), ERIC: 12.70 (-0.09), DIA: 180.06 (+0.80), ING: 14.87 (+0.10)
3 Drug Stocks Leading the Charge Against Infectious Diseases
Brian Orelli, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Sat Apr 18, 2:02PM CDT
Infectious disease has become a hot sector recently thanks to Gilead Sciences ' instant-blockbuster hepatitis C drugs, Harvoni and Sovaldi -- but there's more to the infectious diseases than hepatitis C. We asked our team of healthcare experts...
DVAX: 23.41 (-0.07), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), GSK: 46.57 (-0.67)
Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle
CNW Group - Fri Apr 17, 8:20PM CDT
The issue:
GSK: 46.57 (-0.67)
Veeva's Latest Solution to Ease Medical Product Rollouts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 6:44PM CDT
Veeva Systems (VEEV) recently launched Veeva KOL Data & Services at the ExL Pharma Medical Affairs Strategic Summit. The latest offering from Veeva is expected to help life sciences companies gain a better understanding of their various stakeholders
VEEV: 27.12 (+0.28), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), GSK: 46.57 (-0.67)
China's Economy Is Surging 7% but Everyone Thinks That's Too Slow
at The Street - Fri Apr 17, 3:08PM CDT
While China is still mustering 7% expansion, many foreign companies have been spoiled by the country's prior supersized growth rates.
BTU: 4.87 (+0.06), BHP: 47.80 (+1.55), MCD: 97.84 (+2.97), GSK: 46.57 (-0.67), AAPL: 128.62 (+1.71), BABA: 82.05 (-0.37)
Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom
at The Street - Fri Apr 17, 7:51AM CDT
Health care stocks are up 33% over the last 12 months, nearly doubling the return of the S&P 500.
VIVO: 18.89 (+0.01), GEN: 7.28 (+0.08), AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), XLV: 74.35 (+0.12)
Korn Ferry names Dave Pearce as senior client partner in Consumer Practice
M2 - Fri Apr 17, 3:02AM CDT
A provider of talent management solutions, Korn Ferry (NYSE:KFY) revealed on Friday that Dave Pearce has joined as a senior client partner in the Global Consumer Practice based in its Minneapolis office.
WFC: 54.67 (+0.39), GSK: 46.57 (-0.67), KFY: 32.97 (+0.17)
Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)
Dave Pearce Joins Korn Ferry's Consumer Practice
Business Wire - Thu Apr 16, 1:54PM CDT
Korn Ferry (NYSE:KFY), the preeminent authority on leadership and talent, today announced that Dave Pearce has joined the firm as a Senior Client Partner in the Global Consumer Practice. He will be based in the Minneapolis office.
WFC: 54.67 (+0.39), GSK: 46.57 (-0.67), KFY: 32.97 (+0.17)
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.42% Loss
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.57 (-0.67)
GlaxoSmithKline Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.57 (-0.67)
Moll Law Group Considering First Nationwide Class Action Suit Against Maker Of Anti-Nausea Drug Zofran
PR Newswire - Wed Apr 22, 11:15AM CDT
A Chicago law firm said today it is considering filing the first nationwide class action suit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.57 (-0.67)
GlaxoSmithKline (GSK) Roof Leaking Today
at The Street - Wed Apr 22, 9:21AM CDT
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
GSK: 46.57 (-0.67)
Rising Rates? Don't Hold Your Breath
Yieldpig - at Seeking Alpha - Wed Apr 22, 4:32AM CDT
HTGC: 14.00 (+0.18), MAT: 28.36 (+1.14), GSK: 46.57 (-0.67)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.44 (+0.18), GSK: 46.57 (-0.67), CELGZ: 2.87 (+0.04)
Summons Executed in Zofran Lawsuit Alleging Birth Defects
PRWeb - Wed Apr 22, 2:07AM CDT
Attorneys for Zofran lawsuits report progress on one of the first Zofran lawsuits that has been filed nationwide, which they now have pending in U.S. District Court in Northern Alabama.* According to these Zofran lawyers, a summons order has been acknowledged by the defendant, GlaxoSmithKline.
GSK: 46.57 (-0.67)
Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:50PM CDT
Switzerland-based Novartis AG (NVS), one of the leading players in the health care solutions, will be reporting its first-quarter 2015 results on Apr 23, 2015.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
ChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors
GlobeNewswire - Mon Apr 20, 5:30AM CDT
ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that Jeff Baxter has joined the Company's Board of Directors as an Independent Director.
IMDZ: 26.66 (+0.22), VBIV: 2.65 (+0.01), GSK: 46.57 (-0.67)
The Weekender
Aviate - at Seeking Alpha - Sun Apr 19, 4:54AM CDT
But it is April Investors were scratching their heads trying to find reasons to justify this week's fall in markets: a potential Grexit, rising peripheral spreads, a slowing rate of incline in bank-lending to corporates (BLS), higher...
TI: 11.62 (-0.04), ALU: 4.12 (+0.09), GSK: 46.57 (-0.67), UL: 44.49 (-0.49), DEO: 112.35 (+0.02), NOK: 8.00 (+0.16), SPY: 210.63 (+1.03), NVO: 56.37 (-0.17), QQQ: 108.65 (+0.59), ERIC: 12.70 (-0.09), DIA: 180.06 (+0.80), ING: 14.87 (+0.10)
3 Drug Stocks Leading the Charge Against Infectious Diseases
Brian Orelli, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Sat Apr 18, 2:02PM CDT
Infectious disease has become a hot sector recently thanks to Gilead Sciences ' instant-blockbuster hepatitis C drugs, Harvoni and Sovaldi -- but there's more to the infectious diseases than hepatitis C. We asked our team of healthcare experts...
DVAX: 23.41 (-0.07), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), GSK: 46.57 (-0.67)
Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle
CNW Group - Fri Apr 17, 8:20PM CDT
The issue:
GSK: 46.57 (-0.67)
Veeva's Latest Solution to Ease Medical Product Rollouts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 6:44PM CDT
Veeva Systems (VEEV) recently launched Veeva KOL Data & Services at the ExL Pharma Medical Affairs Strategic Summit. The latest offering from Veeva is expected to help life sciences companies gain a better understanding of their various stakeholders
VEEV: 27.12 (+0.28), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), GSK: 46.57 (-0.67)
China's Economy Is Surging 7% but Everyone Thinks That's Too Slow
at The Street - Fri Apr 17, 3:08PM CDT
While China is still mustering 7% expansion, many foreign companies have been spoiled by the country's prior supersized growth rates.
BTU: 4.87 (+0.06), BHP: 47.80 (+1.55), MCD: 97.84 (+2.97), GSK: 46.57 (-0.67), AAPL: 128.62 (+1.71), BABA: 82.05 (-0.37)
Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom
at The Street - Fri Apr 17, 7:51AM CDT
Health care stocks are up 33% over the last 12 months, nearly doubling the return of the S&P 500.
VIVO: 18.89 (+0.01), GEN: 7.28 (+0.08), AZN: 73.35 (+0.65), GSK: 46.57 (-0.67), XLV: 74.35 (+0.12)
Korn Ferry names Dave Pearce as senior client partner in Consumer Practice
M2 - Fri Apr 17, 3:02AM CDT
A provider of talent management solutions, Korn Ferry (NYSE:KFY) revealed on Friday that Dave Pearce has joined as a senior client partner in the Global Consumer Practice based in its Minneapolis office.
WFC: 54.67 (+0.39), GSK: 46.57 (-0.67), KFY: 32.97 (+0.17)
Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)
Dave Pearce Joins Korn Ferry's Consumer Practice
Business Wire - Thu Apr 16, 1:54PM CDT
Korn Ferry (NYSE:KFY), the preeminent authority on leadership and talent, today announced that Dave Pearce has joined the firm as a Senior Client Partner in the Global Consumer Practice. He will be based in the Minneapolis office.
WFC: 54.67 (+0.39), GSK: 46.57 (-0.67), KFY: 32.97 (+0.17)
